Researches had shown that the EGFR pathway was the most important target for CRC therapy.41 Two FDA‐approved monoclonal antibodies against EGFR have become clinically routine, but only a small part of patients had an effective result.42, 43 Thus, the development of combinatory therapeutic target should be introduced into CRC therapy.44 In this study, we found that DCA accelerated intestinal carcinogenesis through activation of ADAM‐17/EGFR signalling axis. The gene discussed is ADAM17; the disease is colorectal carcinoma.